Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc; Eisai Inc; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc; Puma Biotechnology; and Seattle Genetics.

Community Practice Connections™: 19th Annual International Congress on the Future of Breast Cancer®

Release Date: September 30, 2020
Expiration Date: September 30, 2021

Activity Overview

Breast cancer is a heterogeneous disease, with several distinct biologic subtypes characterized by differing sensitivity to current therapies and various oncogenic targets that can be exploited for therapeutic gain. Detailed insight into disease characteristics is driving the evolution of more effective treatment strategies and increasingly individualized patient care. The accepted treatment standard now incorporates knowledge of each patient’s tumor biology, the use of biomarkers and molecular assays, careful assessment of the benefit-risk ratio for different therapies in the context of patient comorbidities, and integration of patient preferences.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 19th Annual International Congress on the Future of Breast Cancer®, held in July 2020. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with breast cancer, putting recent clinical trial data into clinical context. The program is designed to inform those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc; Eisai Inc; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc; Puma Biotechnology; and Seattle Genetics.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Integrate results from genomic and/or molecular biomarker assays as appropriate to personalize treatment selection for patients with breast cancer;
  • Incorporate results from recent clinical trials of endocrine, cytotoxic, targeted, bone-modifying, and/or immunotherapeutic agents into personalized treatment plans to optimize outcomes for patients with breast cancer; and
  • Discuss the potential impact of emerging data from clinical trials investigating novel agents on the management of patients with breast cancer.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Program Chair

Joyce A. O'Shaughnessy, MD
Joyce A. O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX

Disclosures: Consultant/Advisory Board: Novartis, AstraZeneca, Celgene, Lilly, Merck, Pfizer, Seattle Genetics.

Hope S. Rugo, MD, FASCO
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant Research Support: Pfizer, Merck, Novartis, Lilly, Genentech, OBI Pharma, Odonate Therapeutics, Daiichi Sankyo, Eisai, Seattle Genetics, MacroGenics, and Immunomedics; Consultant: Ionis Pharmaceuticals and Celltrion (one time only) Travel: Daiichi Sankyo, Mylan, Pfizer, Amgen, Merck, AstraZeneca, MacroGenics, and Puma Biotechnology.

Joseph A. Sparano, MD
Joseph A. Sparano, MD
Professor of Medicine and Obstetrics, Gynecology, and Women's Health
Albert Einstein College of Medicine
Associate Chairman, Clinical Research
Department of Oncology
Montefiore Medical Center
Bronx, NY

Disclosures: Grant/Research Support: Deciphera Pharmaceuticals Inc and Prescient Therapeutics; Consultant: AstraZeneca, Celgene Corporation, CStone Pharmaceuticals, Cardinal Health Inc, Novartis, Pfizer Inc, Genentech/F. Hoffman-La Roche, and Eli Lilly and Company; Shareholder: MetaStat Inc.

Sara A. Hurvitz, MD, Program Chair
Sara A. Hurvitz, MD, Program Chair
Associate Professor of Medicine, Division of Hematology/Oncology
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica-UCLA Outpatient Hematology/Oncology Practice
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosures: Grant Research Support: Ambrx, Amgen, Arvinas, Bayer, Cascadian Therapeutics, Daiichi Sankyo, Dignitana, Eli Lilly and Company, Genentech, GlaxoSmithKline, Immunomedics, MacroGenics, Medivation, Merrimack Pharmaceuticals, Novartis, OBI Pharma, Pfizer, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, F. Hoffman-La Roche, Seattle Genetics; Travel: Eli Lilly, Novartis, OBI Pharma.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By